Shandong Oriental Ocean Sci-Tech Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 2001 as Yantai Oriental Ocean Development Co., Ltd., Shandong Oriental Ocean Sci-Tech Co., Ltd. (ticker 002086) has grown from an aquatic technology promoter to a diversified public company that listed on the Shenzhen Stock Exchange in 2006, expanded into precision medicine with the 2016 acquisition of Aviog Inc., and reshaped its capital base-issuing 68,650,000 non‑public shares in May 2018 to reach 756,350,000 shares and later increasing total share capital by 1,202,596,500 shares in 2023 to a current outstanding of 1,958,946,500 shares-now forming part of a group structure under Shandong Oriental Ocean Group with about 814 employees; with a market capitalization of approximately 5.31 billion CNY (as of November 18, 2025), the company operates two core units-Marine and Big Health-leveraging 70 national/provincial/municipal research projects, 109 national patents and 19 science & technology awards to breed and process sea cucumbers, turbots, kelp seedlings and high‑value fish, run bonded warehousing and export channels to Japan, Korea, Europe and the U.S., and commercialize in vitro diagnostic reagents, devices and clinical testing services, while reporting sales of 245.97 million CNY and a net loss of 105.4 million CNY for the nine months ended September 30, 2025-details that illuminate its ownership, mission, operational model and revenue streams as it positions itself as a national leader in aquatic industrialization and a growing player in precision medicine

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): Intro

• Founded in 2001 as Yantai Oriental Ocean Development Co., Ltd., focused on aquatic product technology promotion.
• Listed on the Shenzhen Stock Exchange in 2006 under ticker 002086.
• Acquired 100% of Aviog Inc. in 2016 to enter precision medicine and diversify its portfolio.
• Issued 68,650,000 non-public shares in May 2018, taking total share capital to 756,350,000 shares.
• In 2023, increased share capital by 1,202,596,500 shares via capital reserve transfers, bringing total to 1,958,946,500 shares.
• Recognized as a Leading Enterprise of Agricultural Industrialization and a National Aquatic Fine Seed Farm.

• Aquaculture technology and breeding: sale of improved broodstock, seed production, technical services and licensing to aquaculture farms.
• Production and sales of aquatic products: farmed species and processed aquaculture products sold to domestic markets and processors.
• Precision medicine and biotech: R&D, clinical services, reagent/kit development and commercialization following the Aviog Inc. acquisition.
• Technology services and consulting: technical promotion, training, and farm management services for integrated agricultural-industrial projects.
• Asset and capital operations: equity investments, strategic M&A, and capital restructuring (including share issuances and capital reserve transfers) to fund growth and R&D.

• Vertical integration across broodstock, seed production, farming guidance and product processing to capture value across the supply chain.
• R&D-driven model leveraging seed-farm-research feedback loops to improve survival, yield and genetic quality of aquatic species.
• Use of capital markets for growth financing: IPO (2006), non-public share issuance (2018), and large share capital increase (2023) to support expansion and diversification.
• Certification and industry recognition (Leading Enterprise of Agricultural Industrialization; National Aquatic Fine Seed Farm) that underpin market trust and preferential policy support.

• Total share capital (post-2023): 1,958,946,500 shares.
• Major corporate capital events: 68,650,000-share non-public issuance (2018); 1,202,596,500-share capital transfer (2023).
• Listed ticker: 002086.SZ (Shenzhen Stock Exchange).

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): History

• Parent-subsidiary relationship: subsidiary of Shandong Oriental Ocean Group Co., Ltd.
• Public listing: Shenzhen Stock Exchange ticker 002086.SZ; market cap ~5.31 billion CNY (as of 2025-11-18).
• Shares outstanding: 1,958,946,500 (as of 2025-12-05).
• Employees: ~814 staff supporting operations across aquaculture, biotech and logistics.

• Major shareholder: Shandong Oriental Ocean Group Co., Ltd. (parent), which provides strategic direction and capital support.
• Public float: remaining shares traded on Shenzhen Stock Exchange; institutional and retail holders participate via ticker 002086.SZ.
• Leadership aligned with ownership: Chair Le Zhang (also Acting CFO) and General Manager Zhiyuan Che head operations and the Big Health Business Unit, respectively.

• Deliver sustainable, high-quality aquaculture and marine-derived health products through integrated R&D and supply-chain capabilities.
• Leverage biotechnology and cold-chain logistics to extend product value, ensure food safety, and expand into health supplements and biochemical applications.

• Aquaculture production: farming, breeding and primary processing of seafood-revenue from live/fresh/frozen seafood sales and contracted supply agreements with distributors and retailers.
• Biotechnology & Big Health: downstream processing into nutraceuticals, marine bio-actives and health supplements developed via in-house R&D; sales through B2B and B2C channels and licensing where applicable.
• Logistics & cold-chain services: temperature-controlled storage and distribution for the company's own products and third-party customers, enabling value capture through service fees and improved product margins.

• Le Zhang - Chairman and Acting Chief Financial Officer (dual role supports strategic-financial alignment).
• Zhiyuan Che - General Manager; President, Big Health Business Unit (drives biotech and health product expansion).
• Corporate structure designed to integrate group resources with public-company transparency and access to capital markets.

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): Ownership Structure

• Mission: Create sustainable value for customers, employees, shareholders and society via quality aquaculture, seafood processing and marine-biotech solutions.
• Enterprise spirit & concept: Sincere dedication, continuous improvement, strict management and efficiency-driven operations.
• Establishment & management philosophies: Devotion, innovation, good faith, credit and collaborative partnerships.
• Personnel philosophy: People-oriented talent development, safety and welfare prioritization.

• Primary revenue streams: aquaculture operations (farmed shrimp and shellfish), seafood processing and sales, feed and breeding seedling sales, and marine biotechnology products.
• Value chain: broodstock & seed production → pond/raft cultivation → processing & cold-chain logistics → domestic and export sales.
• Profit drivers: production scale, yield improvements, feed cost control, processing margins, and access to export markets.

• Largest shareholder: Shandong Oriental Ocean Group - strategic holding and operational alignment (approx. 32.5%).
• Institutional investors & funds: around 25.0% combined, providing liquidity and governance oversight.
• Management & employees: roughly 3.0% via incentives and stock ownership plans to align interests.
• Public float / retail investors: remaining ~39.5%, driving free float and market pricing sensitivity.

• Board oversight focused on risk management in aquaculture cycles, biosecurity, and export compliance.
• Investment priorities: breeding technology, cold-chain expansion, processing capacity upgrades, and R&D in marine biotech.
• Sustainability: initiatives around responsible feed use, disease control, and reduced environmental impact to protect long-term yields.

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): Mission and Values

• Marine Business Unit - core activities include seawater seedling breeding, aquaculture, aquatic product processing, and bonded warehousing. The unit leverages China's coastal resource endowment and logistics advantages to supply fresh and processed seafood to domestic and export markets.
• Big Health Business Unit - focuses on precision medicine capabilities: immunology products, mass spectrometry platforms, molecular diagnostics, and operation of independent clinical laboratories. This unit supports clinical diagnostics, biotech reagents and testing services, aiming to diversify revenue and capture higher-margin healthcare demand.

• Seed-to-shelf marine integration - broodstock and seawater seedling breeding → controlled aquaculture farms → centralized processing and cold-chain management → bonded warehousing and distribution to domestic/external buyers.
• Health-tech integration - R&D-driven product development (immunology reagents, MS assays, molecular kits) → clinical laboratory testing services and product sales → collaboration with hospitals and diagnostic centers for adoption.
• Shared capabilities - centralized procurement, cold-chain logistics, quality control and regulatory compliance frameworks applied across both units to enhance margin and risk control.

• R&D network - technology centers established in China and the United States to accelerate innovation in both marine biology and precision diagnostics.
• Industry-university-research-application system - deep syncretic innovation model with long-term partners that include Peking University and the Institute of Oceanology, Chinese Academy of Sciences, enabling translational research and technology transfer.
• Project and IP achievements - completed 70 national, provincial and municipal science research promotion projects; obtained 109 national patents; awarded 19 science and technology improvement awards - indicators of sustained innovation output and IP accumulation.

• Integrated marine production chain lowering input costs and improving traceability.
• Bonded warehousing and export facilitation enhancing access to international markets.
• Cross-border R&D presence enabling faster uptake of advanced diagnostic technologies.
• Collaborations with top academic institutions providing pipeline for novel technologies and human capital.

• Sale of aquaculture products (fresh, chilled, frozen and processed seafood) - bulk sales to wholesalers, retailers, and foodservice operators; export sales via bonded warehousing.
• Value-added aquatic processing - higher-margin processing of seafood for convenience/consumer segments and branded products.
• Health products and reagents - manufacturing and sales of immunology and molecular diagnostic kits and mass-spectrometry consumables.
• Clinical laboratory services - fee-for-service diagnostic testing and long-term contracts with hospitals/clinics.
• R&D and technology services - collaborative projects, licensing of patents/technologies and government/industry research funding.

• Scale-up of seawater seedling and farm modernization to raise yield per mu and lower unit production cost.
• Expansion of bonded warehousing and export logistics to increase overseas sales and faster customs clearance.
• Deepening the Big Health unit via targeted acquisitions, lab network expansion and commercializing mass-spectrometry and molecular diagnostic platforms.
• Leveraging academic partnerships to move from research outcomes to industrialized products and clinical services.

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): How It Works

• Primary revenue drivers: breeding & cultivation of sea cucumbers, turbots, kelp seedlings and other high-value marine species.
• Downstream processing: frozen, raw, conditioned, cold-air dried, barbecue, flour-coated and ready-to-cook seafood products for domestic consumption and export.
• International trade facilitation: bonded warehousing, customs clearance, distribution and logistics to support exports and import processing.
• Big Health segment: R&D, manufacture and sale of in vitro diagnostic (IVD) reagents/devices and operation of independent clinical laboratories offering third-party testing services.

• Breeding → Harvesting → Primary processing (freezing, conditioning) → Value-added processing (drying, barbecue, prepared foods) → Domestic retail & foodservice sales.
• Bonded warehousing + logistics → Export dispatch (customs declaration/inspection) → Overseas distribution (Japan, South Korea, Europe, USA).
• R&D & production of IVD reagents/devices → Sales to hospitals/clinics + third-party laboratory testing services → Recurring revenue & service contracts.

• Sea cucumber, turbot and precious fish farming - sale of live or fresh product to wholesalers, retailers and directly to processing lines; premium species command higher margins and export demand.
• Processed seafood - higher-margin packaged and ready-to-cook items sold via retail, e-commerce and foodservice channels; private-label and branded SKUs increase shelf presence and pricing power.
• Export sales - foreign markets (Japan, South Korea, Europe, USA) pay premiums for quality-graded processed seafood; bonded logistics reduce tariff/clearance friction and working capital costs.
• Bonded warehousing & logistics - fee income from storage, distribution and customs facilitation; value captured from integrated supply-chain services for third parties and internal exports.
• IVD reagents/devices & testing services - product sales to medical institutions and recurring revenue from third-party lab testing; clinical labs provide stable, service-based cash flows and cross-sell opportunities with reagent sales.

• Domestic channels: supermarkets, specialty seafood markets, foodservice and online platforms - drives volume and brand recognition.
• International channels: direct exports and distributor partnerships in Japan, South Korea, Europe and the U.S. - support higher ASPs (average selling prices).
• Integrated logistics: bonded warehousing reduces cash conversion cycle for export shipments and enables quicker market response.

• Investment in automated processing and cold-chain infrastructure to reduce per-unit processing costs and spoilage.
• Breeding technology and seedling programs to increase survival rates and yield per hectare, improving raw-material cost stability.
• Scaling of Big Health R&D and clinical lab network to expand high-margin service revenues and leverage reagent sales.
• Expanding bonded warehouse capacity to capture third-party logistics fees and improve export throughput efficiency.

Shandong Oriental Ocean Sci-Tech Co., Ltd. (002086.SZ): How It Makes Money

• Seed production & broodstock sales: selective breeding, high-value seed and parent stock for marine and freshwater species.
• Aquaculture services & tech licensing: farm design, disease control protocols, breeding technologies and licensing of improved strains.
• Processing & product sales: intensive processing of aquaculture products for domestic and export markets, value-added seafood products.
• Biotech & health-sector products: R&D-derived biologics, feed additives, and health-promoting aquaculture inputs developed via in-house R&D centers.
• R&D partnerships & government projects: contract research, national/provincial project funding, and subsidies tied to agricultural industrialization.
• Distribution & logistics: acting as a distribution center and regional hub for new varieties and technologies.

• Designations: Leading Enterprise of Agricultural Industrialization; National Aquatic Fine Seed Farm.
• R&D footprint: technological R&D centers in China and the U.S., enabling cross-border collaboration in marine and health fields.
• Innovation metrics: 70 completed national/provincial/municipal science research promotion projects; 109 national patents; 19 science & technology improvement awards.

• Becoming a distribution center, radiation source, and industrialization demonstration park for new varieties, technologies, and achievements in aquatic products.
• Prioritizing breakthroughs in gene bank construction, introduction and breeding of new aquatic species, improvement of varieties, aquaculture techniques, and intensive processing to expand margins and capture downstream value.